Navigation Links
OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Date:7/20/2009

BOTHELL, WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering. The transaction is expected to provide gross proceeds of $9.5 million to OncoGenex before deducting costs associated with the offering, and will be used primarily for manufacturing activities and general corporate purposes. The parties expect to close the transaction on or about July 24, 2009.

The shares of common stock offered by OncoGenex in this transaction will be issued pursuant to the Company's existing shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on July 17, 2009. There was no placement agent in this transaction.

"These funds strengthen our balance sheet, substantially extending our runway and assisting our advancement toward our primary objective to secure a co-development and commercialization partner for our OGX-011 program," said Scott Cormack, President and CEO of OncoGenex. "It also allows us to continue our planned manufacturing readiness activities to ensure that our phase 3 trials initiate as planned once a partnership for OGX-011 is secured."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Added to Russell Indexes
2. OncoGenex Pharmaceuticals Files Shelf Registration Statement
3. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
6. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
7. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
8. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The FBI recently approved the Promega Pow...ipating in or generating DNA records for the Natio...adison, WI USA (PRWEB) -- The FBI recently approve...e by laboratories participating in, or generating ...IS). NDIS currently contains more than seven milli...
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,...lcompany,today,announcedthatithassubmittedaMAAtoth...ompany,senzymereplacementtherapyindevelopment,fort...keting,applicationforvelaglucerasealfathathasbeens...andCanada. , Basedonaglobalsupplyshortageofth...
(Date:11/24/2009)...ly,November24/PRNewswire/--HealthRoboticstodayanno...groupofselected,investors.ThisrecentlyformedToront...csCanada,Inc.andwillmarket,install,andsupport,Heal...sthe,revolutionaryproductofferingsi.v.STATION(TM),...illalsoprovideassistanceonan"asneeded,basis"toitss...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--CellTherapeutics,Inc....21stAnnualPiperJaffrayHealthCareConference.Theconf...eHotel. ,, CTIwillpresentonTuesday,December1at1...ebcastofCTI,spresentationwillbeavailableat www.cel...ayafterwards. , ,PiperJaffrayHealthCareConference...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ong Commitment to Ethical Information Exchange b...gy and Pharmaceutical Compan... announced,today that the company has adopted and ... PhRMA Code on Interactions with Healthcare Profes...on the prior 2002 version, was,approved unanimousl...
...thene, Inc.,(Amex: PIP ) a biodefense company spe... of medical countermeasures against chemical and,b...Karp, J.D., has been,appointed Senior Vice Preside...an resources matters for PharmAthene., Mr. Karp j...ience in a,variety of areas, including SEC complia...
... access to 'Best Practices for Long-term Jatr... R. Rajagopal's highly successful November 20...stock: Jatropha: A Strategic Option', is bein...inability criterion for Jatropha as it nears comme.... Key points outlined in Dr. R. Rajagopal's l...
Other Biology Technology:EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel 2PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4
(Date:11/23/2009)..., CHAMPAIGN, Ill. A new study provides "incont...ion of Toba on the island of Sumatra about 73,000 ...,000 miles from the epicenter, researchers report....lometers of ash into the atmosphere, leaving a cra...s 100 kilometers long and 35 kilometers wide. Ash ...
(Date:11/23/2009)..., DURHAM, N.H. University of New Hampshire mic...aling $498,115 to advance understanding of the act...ential to enrich nutrient-poor and contaminated so...ure (USDA) awarded Tisa, a professor of molecular,...lore the symbiotic relationship between the bacter...
(Date:11/23/2009)..., , , , , , , , , , ... , , AUDIO: , Dr Andrew Mar...ersity of York, discusses the discovery of Kinyon... , Click here for more information... , , , , , , , ...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2UNH prof. receives nearly $500,000 to research environmentally significant plants 2New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 1Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 2Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 3LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 1LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3
... -- Growing recognition of the importance of healt... and societal change has prompted the Proceedings ...a new subsection in Sustainable Health to its exis...ural subsection, posted online Oct. 3, 2007 includ...vard School of Public Health (HSPH), describing th...
... Sensitive skin . . . , People with tomorrow,s ...t, cold and touch through a series of developments...nd NASA. Two different ORNL research groups, Ilia ...s Synthesis and Properties Group, and John Simpson...ining superhydrophobic material with thin layers o...
... -- If projected increases in the use of corn for ...y could be considerable, and water supply problems..., says a new report from the National Research Cou...d policy options and identified opportunities for ...lp minimize effects of biofuel production on water...
Other Biology News:Data on life expectancy show many countries clustered in high mortality traps 2Data on life expectancy show many countries clustered in high mortality traps 3Story tips from the Department of Energy's Oak Ridge National Laboratory, October 2007 2Increase in ethanol production from corn could significantly impact 2Increase in ethanol production from corn could significantly impact 3
...ns Protein 295 ex can measure three fluorescence l...e in only a few minutes. To match the absorption m...the Protein 295 exs excitation source is the power...uorescence of tryptophan is widely used as a probe...
... cDNA Library Panels were designed for full-length...to identify the desired cDNA clone. The first PCR ... where each well contains plasmid DNA from 5,000 c...el electrophoresis of the reaction products, the s...
... cDNA Library Panels were designed for full-length...to identify the desired cDNA clone. The first PCR ... where each well contains plasmid DNA from 5,000 c...el electrophoresis of the reaction products, the s...
...measuring instrument for calibrating single-channe...act design and the robust carrying case, the MCP1-...boratory and on-site at the users premises. The un... channels are tested automatically. Multi-channel ...
Biology Products: